Study of BI 3034701 for healthy or overweight Japanese people
Part of Hormones & metabolism clinical trials.
This trial tests different doses of a new medicine in healthy Japanese people and those with obesity or overweight. It aims to see how well the body handles the drug and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be Japanese, born in Japan, and have lived outside Japan for less than 10 years.
- You must be between 18 and 64 years old.
- You must be in generally good health based on a medical checkup.
- For part 1, your weight must not have changed by more than 5% in the last 3 months.
- You may have obesity or overweight for part 2.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called BI 3034701 to see how well people tolerate different doses. It may help with weight loss and related health issues.
This study tests how a new medicine (BI 3034701) moves through the body in healthy men who have normal weight or are overweight. It helps find the right dose and understand how the medicine works.
This trial tests an investigational drug called BI 3034701 to see if it helps people lose weight. It is for adults who are obese or overweight with at least one weight-related health problem.
This study tests a new medicine called PF-08653945 to see how it enters the blood in adults who are overweight or have obesity. The results will help doctors understand how the medicine works in the body.
This trial tests a new medicine called AZD1043 in healthy adults who are overweight or have obesity. It aims to see if the medicine is safe and how the body handles it.
This trial tests different doses of UBT251, a new medicine, to see how well it helps people lose weight. It may be an option if you have overweight or obesity and meet certain age and BMI requirements.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.